% | |
---|---|
Female–male | 10–1 |
Age, mean (SD) (range) (y) | 40.5 (10.4) (21–57) |
SSc duration, mean (SD) (range) (y) | 6.5 (5.8) (1–18) |
SSc subsets | |
Limited | 36 |
Intermediate | 18 |
Diffuse | 46 |
Raynauld’s phenomenon | 100 |
Telangectasias | 100 |
Skin digital pitting | 72 |
Cutaneous ulcers | 18 |
Calcinosis | 18 |
Oesophageal dysmotility | 72 |
Lung fibrosis | 91 |
Pulmonary hypertension | 27 |
Heart involvement | 55 |
Autoantibodies1-150 | |
Anti-nuclear | 82 |
Anti-ENA | 46 |
Anti-centromere | 9 |
Anti-Scl70 | 72 |
↵1-150 Anti-ENA: anti-extractable nuclear antigen; anti-Scl70: anti-topoisomerase I antibody.